MICAFUNGIN

Micafungin was initially approved by the United States Food and Drug Administration (FDA) on January 17, 2005.

Micafungin is used to treat a range of serious fungal infections caused by specific types of fungi. It is indicated for the treatment of invasive candidiasis, including candidemia, intra-abdominal candidiasis, and infections of the esophagus caused by Candida species. Additionally, it is used for the treatment of invasive aspergillosis and to initiate empirical antifungal therapy in certain circumstances. It is also used in managing fever in patients with low white blood cell counts (neutropenic fever) often associated with chemotherapy.

Micafungin works by inhibiting the synthesis of a crucial component in the fungal cell wall called beta-glucan. This disruption weakens the structural integrity of the cell wall, leading to increased permeability and ultimately causing the death of the fungal cell.

Common side effects of Micafungin include nausea, vomiting, headache, elevated liver enzyme levels, rash, and pain at the injection site. In some cases, patients might experience diarrhea or itching. Serious side effects are rare but can include severe allergic reactions, infusion reactions during or after administration, and adverse effects on liver function.

Micafungin can cause severe hypersensitivity reactions in individuals with a known allergy to the medication or its components.This medication may affect liver function, leading to elevated liver enzyme levels. It can interact with other medications, affecting their metabolism or efficacy.

Seek immediate medical attention if you experience symptoms such as difficulty breathing, swelling, or rash after taking Micafungin. Regular monitoring of liver function is recommended during treatment.Inform your healthcare provider about all medications, supplements, and herbal products you are taking to prevent potential interactions.

Provide your healthcare provider a complete medical history, including any allergies, liver problems, or other significant conditions before using Micafungin. Regularly monitor your liver function, and if you experience symptoms like jaundice or abdominal pain, tell your healthcare provider. During its infusions, watch for signs of infusion reactions like fever or difficulty breathing. If you have a weakened immune system, are on immunosuppressive medications, or have kidney problems, discuss the risks and benefits with your healthcare provider. Additionally, consider your age, underlying medical conditions, and the necessity of following up with scheduled appointments to monitor progress and potential side effects. By sticking to these precautions,consulting with your healthcare provider, you can ensure the safe and effective use of this medication.

Flynn Pharma Ltd, Electronic Medicines Compendium (EMC), [Revised on 21 Sep 2022] [Accessed on 23rd August 2023], https://www.medicines.org.uk/emc/product/11840/pil#gref Astellas Pharma US, Inc., US Food & Drug Administration, [Revised on 7/2021] [Accessed on 23rd August 2023], / https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212125s000lbl.pdf Harry W. Lampiris, Daniel S. Maddix, Antifungal Agents, Lange’s Basic & Clinical Pharmacology, 14th Edition, 2018, 853-862.